These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15670947)

  • 1. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
    Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
    Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A; Luppi A; Avallone R; Baraldi M
    Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
    Smith VB; Spina D
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of PDE4 inhibitors in asthma or COPD.
    Spina D
    Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are phosphodiesterase 4 inhibitors just more theophylline?
    Boswell-Smith V; Cazzola M; Page CP
    J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
    Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.
    Dastidar SG; Rajagopal D; Ray A
    Curr Opin Investig Drugs; 2007 May; 8(5):364-72. PubMed ID: 17520865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
    Xia XD; Dai YR; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
    [No Abstract]   [Full Text] [Related]  

  • 12. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ; Cortijo J; Morcillo EJ
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CC-10004 .
    Khobzaoui M; Gutke HJ; Burnet M
    Curr Opin Investig Drugs; 2005 May; 6(5):518-25. PubMed ID: 15912967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.
    Halpin DM
    Br J Hosp Med (Lond); 2006 Jul; 67(7):370-4. PubMed ID: 16884152
    [No Abstract]   [Full Text] [Related]  

  • 18. Phthalazine PDE IV inhibitors: conformational study of some 6-methoxy-1,4-disubstituted derivatives.
    Haack T; Fattori R; Napoletano M; Pellacini F; Fronza G; Raffaini G; Ganazzoli F
    Bioorg Med Chem; 2005 Jul; 13(14):4425-33. PubMed ID: 15927474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
    Gutke HJ; Guse JH; Khobzaoui M; Renukappa-Gutke T; Burnet M
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1149-58. PubMed ID: 16312137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.